C-265, An Act to amend the Food and Drugs Act (List of Therapeutic Products Pre-approved for Special Access), would amend the federal Food and Drugs Act. Its stated goal is to streamline access to treatment for serious or life-threatening conditions and where there is an unmet need. These are proposed changes, not provisions in force; if enacted, the bill would come into force one year after royal assent.
No cost information is in the available material.
Summary matches the latest captured text
Summary version: First Reading · 2026-03-11
Last source check:
Read the latest official textBills on related subjects, starting with Canada.
This bill could speed up reviews for new psychedelic drugs, potentially helping patients. It does not guarantee approval or change who can receive treatment.
Status
First reading
It would push health information technology to work together and stop data blocking, aiming to improve access to your health information. Details and costs will come from future regulations.
Status
Second reading
Lawmakers would amend the Food and Drugs Act to cover natural health products, but published text shows no operative provisions or cost details.
Status
Consideration in committee
It would speed up approvals for some farm products using foreign reviews. This could mean faster access to seeds and pest products, with safety rules to protect people.
Status
First reading